RxDoctor Payments Data

Mark Lahtinen, DO

Family Medicine · Spokane, WANPI 1285291740

Payments from drug & device makers

$10,224in general payments, 2019–2025

Across 483 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$1K
  • AstraZeneca$982
  • Johnson & Johnson$720
  • Boehringer Ingelheim$652
  • Novo Nordisk$567
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$9,94697%
  • Education$2783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,224 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$61,736
Medicare patients
144
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$94,903
EliquisApixaban62$67,471
FarxigaDapagliflozin Propanediol66$66,925
JardianceEmpagliflozin57$66,025
XareltoRivaroxaban38$33,502
RelistorMethylnaltrexone Bromide17$27,144
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$25,842
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$24,825
RybelsusSemaglutide20$23,100
ProliaDenosumab12$21,219
Aimovig AutoinjectorErenumab-Aooe12$19,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$9,933
SymbicortBudesonide/Formoterol Fumarate22$7,902
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen239$7,381
Diclofenac Epolamine14$4,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$567$118,003101 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$982$99,653128 claims
PfizerEliquis$538$67,47162 claims
Boehringer IngelheimJardiance$652$66,02557 claims
Johnson & JohnsonXarelto$720$33,50238 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$257$27,14417 claims
GSKTrelegy Ellipta$272$25,84231 claims
AmgenProlia$327$21,21912 claims
Sanofi-aventis U.S. LLCLantus$15$1,88719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →